Compare Twist Bioscience Corp (TWST) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs VF Corp — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while VF Corp trades at $12.94 (market cap $5.19B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and VF Corp pays a 2.73% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | VFC | |
|---|---|---|
Market Cap | $8.42B | $5.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $21.55 |
52-Week Low | $24.16 | $12.91 |
Enterprise Value | $8.35B | $9.47B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VFC trades at $13.20, down 1.86% on the day, with a bearish technical outlook despite attractive valuation metrics including a P/E of 19.13 and P/S of 0.55. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The company faces challenges with Vans brand weakness offsetting strength in Outdoor brands, though management has raised fiscal 2027 sales guidance. Cash flow trends show improvement with 2026 projecting positive net cash flow of $32 million.
The investment case balances discounted valuation against execution risks. Analyst consensus leans neutral with a $17.38 price target representing 32% upside potential. Key risks include persistent Vans underperformance, consumer sentiment headwinds, and debt management challenges. The turnaround story depends on successful brand execution and margin improvement in the second half of 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
